Holen Sie sich die Stockscreener-App
3.10
6.16%
0.18
Handel nachbörslich:
3.10
Schlusskurs vom Vortag:
$2.92
Offen:
$2.975
24-Stunden-Volumen:
3.30M
Relative Volume:
1.24
Marktkapitalisierung:
$827.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-244.17M
KGV:
-3.1753
EPS:
-0.9763
Netto-Cashflow:
$-144.77M
1W Leistung:
-0.96%
1M Leistung:
-25.66%
6M Leistung:
-8.55%
1J Leistung:
+44.19%
1-Tages-Spanne:
$2.961
$3.19
1-Wochen-Bereich:
$2.86
$3.33
52-Wochen-Spanne:
$1.26
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Firmenname
Sana Biotechnology Inc
Sektor
Branche
Telefon
(206) 701-7914
Adresse
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.10 | 779.25M | 0 | -244.17M | -144.77M | -0.9763 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | Wedbush | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-03-18 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-01-08 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-11-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-01-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-08-14 | Eingeleitet | TD Cowen | Market Perform |
| 2023-05-02 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-03-01 | Eingeleitet | BofA Securities | Buy |
| 2021-03-01 | Eingeleitet | Goldman | Neutral |
| 2021-03-01 | Eingeleitet | JP Morgan | Neutral |
| 2021-03-01 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2%Here's What Happened - MarketBeat
Shorts Report: How does Sana Biotechnology Inc score in quality rankingsMarket Sentiment Review & Accurate Intraday Trade Tips - baoquankhu1.vn
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sana Biotechnology (SANA) appoints industry veteran Brian Piper as new CFO - MSN
SANA Forecast, Price Target & Analyst Ratings | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Bull Run: Will Sana Biotechnology Inc stock hit new highs in YEAR2026 Outlook & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Breakouts Watch: Can Sana Biotechnology Inc be the next market leaderDay Trade & High Accuracy Buy Signal Tips - baoquankhu1.vn
H.C. Wainwright reiterates Sana Biotechnology stock buy rating - Investing.com
Sana Biotechnology reports 14-month data on diabetes cell therapy By Investing.com - Investing.com India
Integral Health Asset Management LLC Has $7.10 Million Stock Position in Sana Biotechnology, Inc. $SANA - MarketBeat
Morgan Stanley Maintains Overweight on Sana Biotechnology, Inc. (SANA) March 2026 - Meyka
Morgan Stanley reiterates Sana Biotechnology stock rating on diabetes data By Investing.com - Investing.com Canada
Sana Biotechnology (NASDAQ:SANA) Trading Up 7.8%Here's What Happened - MarketBeat
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression - Bitget
Sana Biotechnology reports 14-month data on diabetes cell therapy - Investing.com
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Earnings Report: Will Sana Biotechnology Inc benefit from sector rotation2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
SANA: Hypoimmune and in vivo CAR T platforms advance toward clinical trials, with key data expected soon - TradingView
Sana (SANA) CEO Steve Harr vests RSUs and uses 24,345 shares for tax - Stock Titan
Sana Biotechnology (SANA) officer exercises RSUs and withholds shares for taxes - Stock Titan
VIX Spike: Can Sana Biotechnology Inc be the next market leader2026 Chart Watch & Comprehensive Market Scan Reports - baoquankhu1.vn
Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors - Sahm
SANA Should I Buy - Intellectia AI
Aug Drivers: Is Sana Biotechnology Inc attractive at current valuation2025 Market Trends & Short-Term High Return Ideas - baoquankhu1.vn
Sana Biotechnology (SANA) CEO granted 200,000 RSUs and 900,000 stock options - Stock Titan
TD Cowen reiterates Buy rating on Sana Biotechnology stock By Investing.com - Investing.com Canada
TD Cowen reiterates Buy rating on Sana Biotechnology stock - Investing.com UK
Q1 EPS Estimate for Sana Biotechnology Lowered by Analyst - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 9.7% After Analyst Downgrade - MarketBeat
What is HC Wainwright's Forecast for SANA FY2030 Earnings? - MarketBeat
Seattle InnoCajal raises $96M I Layoffs at Sana - The Business Journals
Sana Biotechnology (NASDAQ:SANA) Cut to Hold at Zacks Research - MarketBeat
Citizens reiterates Sana Biotechnology stock rating on pipeline progress By Investing.com - Investing.com Nigeria
AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks - TipRanks
Sana Biotechnology (SANA) officer exercises RSUs, uses 491 shares for taxes - Stock Titan
Sana Biotechnology Diabetes Data And CAR T Plans Shape Pipeline Outlook - simplywall.st
Sana Biotechnology (SANA) Q4 2025 Financial Results: Net Loss and Analyst OutlookNews and Statistics - IndexBox
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $7.00 at HC Wainwright - MarketBeat
Sana Biotech's Q4 Net Loss Expands; Plans To Submit IND For SC451 In 2026; Stock Down - Nasdaq
Sana Biotechnology files for mixed shelf size not disclosedSEC filing - marketscreener.com
Sana Biotechnology Files For Mixed Shelf Size Not DisclosedSEC Filing - TradingView
Sana Biotechnology (NASDAQ: SANA) files ATM to raise up to $150M with TD Cowen - Stock Titan
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - Bitget
Sana: Overview of Fourth Quarter Financial Results - Bitget
Sana Biotechnology Updates ATM Program to Support Development - TipRanks
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q4 Adjusted Loss $0.16 per Share, vs. FactSet Est of $-0.14 - marketscreener.com
Going concern risk and focused pipeline at Sana Biotechnology (NASDAQ: SANA) - Stock Titan
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Sana Biotechnology (NASDAQ: SANA) sets $150.0 million ATM program - Stock Titan
SANA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Finanzdaten der Sana Biotechnology Inc-Aktie (SANA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):